NICE decision on Lenvatenib and Sorafenib

July 13th, 2018
NICE have finally given their decision on Lenvatenib and Sorafenib.
Both drugs are recommended for the treatment of thyroid cancer which is no longer taking up RAI.
However,patients can only have access to one of the drugs.
This means that patients who are already taking Sorafenib will not be able to have Lenvatenib when and if they need it.
This is a dreadful decision.
The only exception is if a patient had has Sorafenib and had to withdraw from it due to toxicity.
We await comments from NHS E England on this .

Leave a Reply

Your email address will not be published. Required fields are marked *

We are available on this number on Tuesdays and Fridays from 10 am to 4 pm. Outside these times, please leave a message on our answer phone and we will get back to you as soon as we can.